RSSNewsletterSiteMapFeedback

Home · Weather · Forum · Learning Chinese · Jobs · Shopping
Search This Site
China | International | Business | Government | Environment | Olympics/Sports | Travel/Living in China | Culture/Entertainment | Books & Magazines | Health
Home / China / National News Tools: Save | Print | E-mail | Most Read
Imports of blood drug approved
Adjust font size:

The top drug authority is set to approve imports of a hemophilia treatment to help make up for a shortfall that has deprived some patients of the medication they need.

The recombinant-clotting factor produced by the German pharmaceutical company Bayer Healthcare will be on the market soon, according to an announcement on the State Food and Drug Administration (SFDA) website.

"This does not mean that we are easing the two-decade ban on imported blood and plasma-derived products of all kinds," SFDA spokeswoman Yan Jiangying said yesterday.

The authorities imposed the ban in 1986, in response to a case of HIV infection caused by imported factor VIII that was detected around 1983.

The German-made treatment does not fall into the categroy of products that are subject to the embargo because it is not made from human plasma, said Yin Hongzhang, a division director with the SFDA's department of drug registration.

However, the recombinant-clotting factor has the same medical effect as plasma-derived factor VIII. It is widely used to treat hemophiliacs in China.

Many clinicians believe such treatments pose little risk of transmitting an infectious disease.

Larry Zhang, regional head for Asia Pacific of Bayer Healthcare, said the treatment would be made available at a lower price in China than in other countries because of the financial difficulties that many patients here face and the lack of a comprehensive health insurance scheme.

Recombinant-clotting factor will cost no more than 5 yuan (0.65 US dollar) in China, Zhang said. The average international price is 30 yuan.

A unit of factor VIII currently costs more than 1 yuan in China. In case of a hemorrhage, 1,000 units are required to stop a potentially fatal bout of bleeding.

Chu Yuguang, a Beijing-based hemophiliac and the director of the Hemophilia Home of China, a volunteer group of more than 3,000 patients, applauded the plan to import recombinant-clotting factor, describing it as as a timely measure by the government.

"However, many patients cannot even afford locally made factor VIII, let alone the much more expensive import," Chu said.

In another development, recombinant-clotting factor donated by Bayer Healthcare, enough for roughly 650 patients, is on its way from the US to China and should arrive at six Chinese hospitals next week, Zhang said.

(China Daily September 20, 2007)

Tools: Save | Print | E-mail | Most Read

Comment
Username   Password   Anonymous
 
China Archives
Related >>
- Blood Drug: No Hepatitis C Infection Found
- Blood-Based Drug Suspected of Spreading Hepatitis C
- Illegal Blood Procurement in Hepatitis C Scandal
- MOH Bans the Use of Hepatitis C-causing Blood Drug
Most Viewed >>
-Fog worsens central China's traffic logjam
-Stampede leaves 1 dead in Guangzhou Railway Station
-Donations appealed for snow victims
-Winter storms leave Chinese dark, cold, hungry in 'dead cities'
-Millions stranded in holiday havoc
SiteMap | About Us | RSS | Newsletter | Feedback

Copyright ? China.org.cn. All Rights Reserved E-mail: webmaster@china.org.cn Tel: 86-10-88828000 京ICP證 040089號

主站蜘蛛池模板: 久久精品九九亚洲精品| 亚洲精品第一国产综合精品| 91香蕉成人免费网站| 国产色爽女小说免费看| japanese日本熟妇多毛| 成人人免费夜夜视频观看| 久久久无码人妻精品无码| 暖暖免费高清日本中文| 亚洲国产日韩在线成人蜜芽| 波多野结衣与老人| 伊人精品视频一区二区三区| 精品国产免费观看久久久| 国产一区二区三区樱花动漫| 龙珠全彩里番acg同人本子 | 日韩亚洲欧美一区| 亚洲中文字幕在线第六区| 欧美日韩第一区| 亚洲欧美视频在线| 特大巨黑吊aw在线播放| 偷自拍亚洲视频在线观看99| 精品人妻少妇一区二区三区| 啊轻点灬大ji巴太粗太长h | 精品人妻中文字幕有码在线| 同桌一直在夹腿还嗯啊的叫| 老熟妇仑乱一区二区视頻| 国产乱人伦偷精品视频| 青青草原综合久久大伊人| 国产性夜夜春夜夜爽| 97国产在线视频公开免费 | 国产伦一区二区三区高清| 高级别墅贵妇交换俱乐部小说| 国产无人区卡一卡二卡三网站| 色一情一乱一乱91av| 国产特级毛片aaaaaa高清| 豆奶视频最新官网| 国产精品亚洲精品日韩已满| 18禁止午夜福利体验区| 国产精品无码无卡无需播放器| 亚洲国产精品日韩专区av| 欧美高清在线精品一区 | 亚洲国产一二三精品无码|